Blog

Unlock the Editor’s Digest for free

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.

The head of the UK arm of Fujitsu, the technology group at the centre of the Post Office Horizon scandal, received a 50 per cent pay rise last year as its parent company injected fresh capital to offset falling orders and reputational damage.

Accounts for UK-based Fujitsu Services, a subsidiary of the Japanese IT services company, show its highest-paid director — understood to be UK head Anwen Owen — earned £591,000 in the year to March 2025, up from £388,000 a year earlier. Owen, a former senior civil servant who joined the UK company’s board in 2022, previously held roles at the Treasury and Cabinet Office.

According to the accounts, Fujitsu’s parent injected £80mn into the business to “strengthen the balance sheet” and support operations, following a £200mn capital infusion the previous year.

Revenues fell 9.2 per cent to almost £1.1bn, while profit recovered to £15mn from a loss the year before. However, the company’s order pipeline contracted by a fifth to £904mn, with management warning that the “loss of future new business due to reputational damage arising from the Horizon inquiry remains a key risk”.

More than 900 sub-postmasters were wrongly prosecuted between 1999 and 2015 due to faults in the Horizon computer system, which was developed by Fujitsu and falsely showed accounting shortfalls. More than 230 sub-postmasters were jailed, and at least 13 are believed to have taken their own lives.

In its latest filings, Fujitsu said it “continues to support the inquiry process until its conclusion” and is “engaging in discussions with the UK government regarding an appropriate and proportionate contribution” to compensation for victims.

The company said ahead of the inquiry’s final findings, “it is not possible to estimate the amount of a future financial contribution” and therefore no provision has been made in its balance sheet.

The pay rise and cash injection were first reported by the Times and the Sunday Telegraph.

Fujitsu has suspended bidding for UK government contracts until the conclusion of the public inquiry into the Horizon system.

The company told the Financial Times that it continued to work with the government “to ensure we adhere to the voluntary restrictions we put in place regarding bidding for new contracts” and was “engaged with government regarding Fujitsu’s contribution to compensation”.

It added that “improved operating margins and the successful delivery of strategic cost reduction measures” had helped boost pre-tax profits.

“We remain focused on supporting our UK customers, through the delivery of innovative IT services and solutions,” the company said.

The UK government last week pledged to improve the compensation schemes for victims of the Horizon scandal. Business secretary Peter Kyle said ministers would create an appeals process for sub-postmasters who accepted fixed-sum payments under earlier settlements, allowing them to pursue full, evidence-based redress.

The first report of the public inquiry, released in July, found that both Post Office and Fujitsu employees were aware of serious flaws in the Horizon system but “maintained the fiction” that it was reliable. The government has accepted all but one of the inquiry’s 19 recommendations, including proposals for an independent body to oversee redress in future cases.

Fujitsu’s accounts also disclose a £4mn damages claim filed by a former sub-postmaster in July. Fujitsu does not identify the claimant, but media reports have linked the case to Lee Castleton, whose story featured in ITV’s Mr Bates vs the Post Office. The company said it was “not yet possible to predict the outcome” of the case.

Welcome to this week’s edition of The Targeted Pulse, your weekly wrap-up of the top developments in oncology. This week, we saw several breakthroughs in targeted therapies and FDA decisions, bringing renewed hope to patients and clinicians alike. From regulatory designations for promising new drugs to crucial clinical trials, here are the top stories that shaped the week.

Low-Dose Nivolumab Offers Novel Strategy for Hodgkin Lymphoma Treatment

A phase 2 study found that a low-dose regimen of the immunotherapy drug nivolumab (Opdivo; 40 mg) combined with lenalidomide is a highly effective, chemotherapy-free strategy for classical Hodgkin lymphoma (cHL). The combination achieved an overall response rate of 90% with a favorable safety profile.

Crucially, researchers observed that the 40 mg dose was sufficient to achieve complete PD-1 receptor occupancy, suggesting that the standard, higher nivolumab dosing may be excessive. The findings advocate for using pharmacodynamic biomarkers to guide personalized, cost-effective dosing schedules. This evidence-based approach challenges traditional dosing models, offering a path to significantly reduce treatment costs and improve global access to nivolumab, especially in resource-limited areas. A phase 3 trial is currently underway to compare this novel low-dose regimen with the standard ABVD chemotherapy.

FDA Approves Lurbinectedin/Atezolizumab for ES-SCLC Maintenance

The FDA has approved the combination of lurbinectedin (Zepzelca) and the immunotherapy atezolizumab (Tecentriq) for first-line maintenance treatment in patients with extensive-stage small cell lung cancer (ES-SCLC). This regimen is for patients whose disease has not progressed after initial induction therapy.

The approval is based on the phase 3 IMforte trial, which demonstrated statistically significant improvements in survival. Compared to atezolizumab alone, the combination reduced the risk of disease progression or death by 46% and the risk of death by 27%, with a median overall survival of 13.2 months. This maintenance strategy addresses a critical need in ES-SCLC to proactively prevent aggressive relapse.

FDA Approves Cemiplimab for Adjuvant Cutaneous Squamous Cell Carcinoma

The FDA has approved the immunotherapy cemiplimab-rwlc (Libtayo) as the first and only adjuvant treatment for adults with high-risk cutaneous squamous cell carcinoma (CSCC) following surgery and radiation.

This approval is based on the phase 3 C-POST study, which demonstrated that cemiplimab significantly improved disease-free survival (DFS). The treatment reduced the risk of cancer recurrence or death by 68% compared with placebo, addressing a critical unmet need for patients with a high risk of relapse. The findings also showed an 80% reduction in locoregional recurrence risk, marking a practice-changing milestone in preventing recurrence for this vulnerable population.

Orca-T Earns FDA Priority Review in Heme Malignancies

The FDA granted priority review to the biologics license application (BLA) for Orca-T, an investigational allogeneic T-cell immunotherapy for treating high-risk hematologic malignancies, including AML, ALL, and MDS. The priority review is based on data from the phase 3 Precision-T study. This trial showed that Orca-T significantly improved patient outcomes compared to standard allogeneic hematopoietic stem cell transplant (alloHSCT), particularly in achieving survival free of chronic graft-vs-host disease (cGVHD). Specifically, Orca-T achieved a high survival rate with a much lower incidence of moderate to severe cGVHD (13% vs 44%). This milestone aims to provide a potentially curative option with reduced treatment-related complications.

Dato-DXd Delivers Significant TNBC Survival Benefits in Phase 3 Trial

The antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd; Datroway) showed statistically significant improvements in both overall survival (OS) and progression-free survival (PFS) for the first-line treatment of metastatic triple-negative breast cancer (TNBC). The pivotal phase 3 TROPION-Breast02 trial demonstrated that Dato-DXd was superior to standard chemotherapy for patients for whom immunotherapy was not a treatment option. This is the first trial to show an OS benefit in this challenging patient population, suggesting a potential shift in the standard of care for a disease often associated with a poor prognosis.